Overdose may cause neurological, cardiovascular, and anticholinergic toxicity. Multi-dose activated charcoal (MDAC) enhances CBZ elimination.

Toxicity / Risk Assessment

Onset of severe clinical toxicity can be delayed

One 400 mg tablet may cause severe toxicity in a child

Symptom severity	Dose ingested (mg/kg)	Concentration in umol/L (mg/L)
Mild/none	<20	Up to 85 (20)
Moderate	20-50	85-170 (20-40)
Severe	>50	>170 (>40)

Clinical features:

Mild: drowsiness, nystagmus, tachycardia, dry mouth,	
ataxia, dysarthria	
Moderate: increasing sedation, delirium with	
intermittent agitation, urinary retention	
Severe: coma, hypotension, arrhythmias, seizures,	
respiratory depression, ileus	
CVS toxicity : may include ↓BP, ↑QRS (Na channel	
blockade), ventricular arrhythmias	
Large ingestions: delayed absorption / anticholinergic	
effects may lead to cyclical clinical toxicity	

Management: primarily supportive; intubation may be required in cases of significant CNS depression **Decontamination**:

Activated Charcoal 50 g (Paediatric: 1g/kg) should be given for ingestion >20 mg/kg in awake patients Patients with severe toxicity should receive activated charcoal 50 g via NGT post intubation

Investigations: Symptomatic patients - check serum CBZ concentration 4-6 hourly until consistently falling **Hypotension** – treat initially with 20 mL/kg IV crystalloid

Wide QRS and Na channel blockade (variable response to 8.4% NaHCO₃) – discuss with clinical toxicologist

- 1 mL/kg 8.4% NaHCO3 solution as slow (2 minutes) IV push. This dose may be repeated if there is a clear

response (narrowing of QRS duration). Monitor serum pH - serum pH must not exceed 7.55.

Seizures - Benzodiazepines: Diazepam 5mg IV every 5 minutes as necessary

Enhanced elimination (Discuss with clinical toxicologist)

- **Multi-dose activated charcoal (MDAC)** for ingestions >50mg/kg with signs of clinical toxicity

Do not administer to patients with an ileus (see separate MDAC guideline)

Extracorporeal elimination: high flux haemodialysis /charcoal haemoperfusion are preferred modalities
Indications: May be beneficial in severe toxicity (refractory seizures / CVS instability) or conc. > 250 umol/L Endpoint of extracorporeal elimination: ↓serum CBZ concentrations with consistent clinical improvement
Dimensional elimination: ↓serum CBZ concentrations with consistent clinical improvement
Dimensional elimination: ↓serum CBZ concentrations with consistent clinical improvement
Dimensional elimination: ↓serum CBZ concentrations with consistent clinical improvement
Dimensional elimination: ↓serum CBZ concentrations with consistent clinical improvement
Dimensional elimination: ↓serum CBZ concentrations with consistent clinical improvement
Dimensional elimination: ↓serum CBZ concentrations
Serum CBZ concentrations

Disposition

- Discharge pending mental health assessment if asymptomatic with normal observations at:

6 hours if < 50 mg/kg ingested OR 12 hours if > 50 mg/kg ingested

- Advise patients not to drive for at least 72 hours post exposure

AUSTIN CLINICAL TOXICOLOGY SERVICE GUIDELINE

POISONS INFORMATION CENTRE: 13 11 26

Version 3: Published 9/2021. Review 9/2024